EXPANDED ACCESS PROGRAM TO TREAT PATIENTS WITH PREVIOUSLY TREATED METASTATIC PANCREATIC ADENOCARCINOMA WITH DARAXONRASIB
The aim of this EAP is to make daraxonrasib available to eligible patients with pancreatic adenocarcinoma, a serious and life-threatening condition, who have no comparable or satisfactory alternative therapy approved by the FDA.
Why this Research Matters
The aim of this EAP is to make daraxonrasib available to eligible patients with pancreatic adenocarcinoma, a serious and life-threatening condition, who have no comparable or satisfactory alternative therapy approved by the FDA.
Who can Participate
Eligible patients may include those who have progressed on, are intolerant of, or have contraindications to available approved therapies. Patients eligible for the EAP must also be unable to participate in any ongoing clinical trial of daraxonrasib (eg, due to ineligibility criteria or geographic/access limitations). More details about who can and cannot join are on ClinicalTrials.gov. Your study doctor or study team member will review these requirements with you.
Study ID
Protocol Number: 26-1243
More information available at ClinicalTrials.gov: NCT07573215
Meet the Team
Principal Investigator